"Neurotransmitter Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function.
| Descriptor ID |
D018377
|
| MeSH Number(s) |
D27.505.519.625 D27.505.696.577
|
| Concept/Terms |
Neurotransmitters- Neurotransmitters
- Transmitter Substances, Nerve
- Substances, Nerve Transmitter
- Nerve Transmitter Substances
- Neurotransmitter
|
Below are MeSH descriptors whose meaning is more general than "Neurotransmitter Agents".
Below are MeSH descriptors whose meaning is more specific than "Neurotransmitter Agents".
This graph shows the total number of publications written about "Neurotransmitter Agents" by people in this website by year, and whether "Neurotransmitter Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 2 | 3 |
| 2004 | 2 | 2 | 4 |
| 2005 | 1 | 2 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 3 | 3 |
| 2009 | 2 | 0 | 2 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2017 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neurotransmitter Agents" by people in Profiles.
-
Gollion C, De Icco R, Dodick DW, Ashina H. The premonitory phase of migraine is due to hypothalamic dysfunction: revisiting the evidence. J Headache Pain. 2022 Dec 13; 23(1):158.
-
Wu M, White HV, Boehm BA, Meriney CJ, Kerrigan K, Frasso M, Liang M, Gotway EM, Wilcox MR, Johnson JW, Wipf P, Meriney SD. New Cav2 calcium channel gating modifiers with agonist activity and therapeutic potential to treat neuromuscular disease. Neuropharmacology. 2018 03 15; 131:176-189.
-
Maasumi K, Tepper SJ, Rapoport AM. New treatments for headache. Neurol Sci. 2017 May; 38(Suppl 1):145-156.
-
Pani AK, Jiao Y, Sample KJ, Smeyne RJ. Neurochemical measurement of adenosine in discrete brain regions of five strains of inbred mice. PLoS One. 2014; 9(3):e92422.
-
Liquori ME, Christenson RH, Collinson PO, Defilippi CR. Cardiac biomarkers in heart failure. Clin Biochem. 2014 Apr; 47(6):327-37.
-
Giacino JT, Katz DI, Whyte J. Neurorehabilitation in disorders of consciousness. Semin Neurol. 2013 Apr; 33(2):142-56.
-
Newberg AB, Moss AS, Monti DA, Alavi A. Positron emission tomography in psychiatric disorders. Ann N Y Acad Sci. 2011 Jun; 1228:E13-25.
-
Burton NC, Schneider JS, Syversen T, Guilarte TR. Effects of chronic manganese exposure on glutamatergic and GABAergic neurotransmitter markers in the nonhuman primate brain. Toxicol Sci. 2009 Sep; 111(1):131-9.
-
Eisenman LM. Motion sickness may be caused by a neurohumoral action of acetylcholine. Med Hypotheses. 2009 Nov; 73(5):790-3.
-
Ellison JM. A 60-year-old woman with mild memory impairment: review of mild cognitive impairment. JAMA. 2008 Oct 01; 300(13):1566-74.